Targets › ATN1
1 program from 1 company in 3 trials: 3 Phase 1; Neurology; next expected readout Nov 2026.
Transcriptional corepressor. Recruits NR2E1 to repress transcription. (UniProt, P54259)
Open in Phaseline: the race on ATN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| n-Lorem Foundation | nL-ATN1-002 Antisense oligonucleotide targeting ATN1 mRNA | ATN1 | Phase 1 | Dentatorubral-Pallidoluysian Atrophy | Nov 2026 |
Dentatorubral-Pallidoluysian Atrophy (3)
small molecule (1)
n-Lorem Foundation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.